OmniAb to Present Innovative Antibody Discovery Technology at March Investor Conferences

OmniAb to Showcase Innovative Antibody Discovery Technology at Upcoming Conferences

OmniAb, Inc., based in Emeryville, California, is set to highlight its cutting-edge antibody discovery technology during two significant investor conferences in March. The first event, the TD Cowen 45th Annual Health Care Conference, is scheduled from March 3-5 at the Boston Marriott Copley Place. OmniAb's management will present a corporate overview on March 4 at 2:30 p.m. Eastern Time, providing insights into the company's innovative technology and strategic direction. Following this presentation, the management team will engage in one-on-one meetings with potential investors, allowing for in-depth discussions on OmniAb's unique offerings and future plans.

The second event, the 2025 Leerink Partners Global Healthcare Conference, will take place from March 9-12 at the W Hotel South Beach in Miami. On March 12, OmniAb's management will again hold one-on-one meetings with investors. These conferences provide OmniAb with a platform to deepen relationships within the investment community while showcasing its proprietary technology, which is vital for the development of next-generation therapeutics. This strategic engagement aims to foster partnerships with pharmaceutical and biotech companies, further solidifying OmniAb's position as a leader in the antibody discovery space.

Central to OmniAb's innovative approach is its Biological Intelligence™ platform, which enhances the immune systems of its engineered transgenic animals. This technology is crucial for creating an extensive array of antibody repertoires, enabling rapid identification of optimal antibodies for drug development. By utilizing advanced methodologies such as computational antigen design and high-throughput single B cell phenotypic screening, OmniAb is dedicated to discovering fully-human antibodies that demonstrate superior performance, which is essential for addressing critical challenges in the pharmaceutical industry.

In addition to its participation in these conferences, OmniAb is committed to aligning its scientific advancements with the economic interests of its partners. The company offers integrated and customizable solutions, structured agreements that typically involve upfront fees, service revenue, milestones, and royalties on commercial sales. This approach not only facilitates the development of next-generation therapeutics but also establishes a mutually beneficial framework for collaboration with its partners.

For more information on OmniAb's innovative technology and its impact on the biotechnology industry, interested parties can visit the company's website at www.omniab.com.